Brooklyn Investment Group Has $82,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Brooklyn Investment Group boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,131 shares of the medical equipment provider’s stock after acquiring an additional 145 shares during the quarter. Brooklyn Investment Group’s holdings in Hologic were worth $82,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the 3rd quarter valued at about $25,000. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment boosted its stake in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. raised its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Monday, January 13th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Monday, January 13th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.75% of the stock is owned by corporate insiders.

Hologic Stock Performance

NASDAQ:HOLX opened at $69.73 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $15.82 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. Hologic, Inc. has a twelve month low of $68.61 and a twelve month high of $84.67. The stock’s 50-day simple moving average is $74.84 and its 200 day simple moving average is $78.41.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.